Interlaboratory comparison in HercepTest assessment of HER2 protein status in invasive breast carcinoma fixed with various formalin-based fixatives.
Although formalin-based fixatives are used in pathologic laboratories, there is no strictly standardized fixation protocol in Japan. To examine interlaboratory variation caused by different conditions of fixation in the assessment of human epidermal growth factor receptor (HER) 2 status on pathologic tissues, 274 archival invasive breast carcinomas from 5 different laboratories were evaluated using the HercepTest. In 1 laboratory in which 10% neutral buffered formalin was used, as recommended by the manufacturer, the overexpression rate was 22.4% and fell within the statistical expected range (20%-30%) for HER2 overexpression in breast carcinomas. The overexpression rates in the other 4 laboratories, in which either 20% nonbuffered formalin or 15% neutral buffered formalin was used, were near the expected range for HER2 overexpression. To clarify the influence of prolonged formalin fixation on the HercepTest, we compared 1-day with 7-day fixations using 36 cases fixed with 20% nonbuffered formalin. Of the 36 cases, 7 showed 3+ staining with 1-day fixation and sustained the same scoring results with 7-day fixation, although the staining intensities in these cases were reduced with the prolonged fixation. These results indicated that the immunohistochemical assessment of HER2 status with the HercepTest was comparatively resistant to prolonged fixation conditions and provided stable staining results in positive cases, particularly 3+ patients.
Hashizume
Kaoru
K
Department of Biomedical Science, DakoCytomation Co. Ltd., Kakkyoyama 18, Nishinotoin-higashiiru, Shijo-dori, Shimogyo, Kyoto 600-8493, Japan. kaoru.hashizume@dakocytomation.jp
Hatanaka
Yutaka
Y
Kamihara
Yuki
Y
Kato
Tomoyuki
T
Hata
Sakae
S
Akashi
Shizuka
S
Kato
Toshihiko
T
Koyatsu
Junichi
J
Tani
Yoichi
Y
Tsujimoto
Masahiko
M
Tsuda
Hitoshi
H
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology*; D005260:Female; D005557:Formaldehyde; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D015588:Observer Variation; D011933:Reagent Kits, Diagnostic / Q000592:standards; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D016707:Tissue Fixation / Q000379:methods*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D005557:Formaldehyde; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases